The proteomic differences identified here, therefore, are likely to provide a useful resource for exploring the molecular consequences of reduced SMN in motor neurons and for the identification of novel therapeutic targets for SMA. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.